Genmab updates Articles of Association
Genmab A/S furnished updated Articles of Association on Form 6-K, incorporating the report into its existing Form S-8 registration statements.
Rhea-AI Filing Summary
Genmab A/S (GMAB) filed a Form 6-K as a foreign private issuer for September 2026, primarily to furnish an updated Articles of Association as Exhibit 3.1. The filing states that this report is incorporated by reference into Genmab’s existing Form S-8 registration statements.
Positive
- None.
Negative
- None.
Key Terms
foreign private issuer, Form 20-F, Form S-8, Articles of Association
4 terms
foreign private issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Form 20-F regulatory
"whether the registrant files or will file annual reports under cover Form 20-F"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
Form S-8 regulatory
"incorporated by reference in Genmab A/S’s registration statements on Form S-8"
A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.
Articles of Association regulatory
"Exhibit 3.1 | Articles of Association"
A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.
FAQ
What did Genmab A/S (GMAB) report in this September 2026 Form 6-K?
Genmab A/S filed a Form 6-K as a foreign private issuer, primarily to furnish its updated Articles of Association as Exhibit 3.1 and to incorporate this report by reference into several existing Form S-8 registration statements.
How does this Form 6-K affect Genmab (GMAB) Form S-8 registrations?
The Form 6-K is deemed incorporated by reference into Genmab A/S’s Form S-8 registration statements (File Nos. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and becomes part of those registrations from the filing date unless later superseded.
What exhibit is included in Genmab A/S (GMAB) September 2026 Form 6-K?
The Form 6-K includes Exhibit 3.1, described as Articles of Association, indicating that Genmab A/S is furnishing its governing corporate document as part of this report.
What is Genmab A/S’s status in this filing?
Genmab A/S is identified as a foreign private issuer that files annual reports under cover of Form 20-F, consistent with its status as a non-U.S. company reporting under the Securities Exchange Act of 1934.
Who signed the September 2026 Form 6-K for Genmab A/S (GMAB)?
The Form 6-K was signed on behalf of Genmab A/S by Anthony Pagano, who is identified as Executive Vice President & Chief Financial Officer, dated September 9, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
